Literature DB >> 1291083

Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia.

M Galiñanes1, M J Shattock, D J Hearse.   

Abstract

OBJECTIVE: The opening of potassium (K+) channels during regional ischaemia may, by inducing rapid contractile arrest, be an intrinsic energy sparing mechanism. Thus K+ channel openers (for example, lemakalim) exert significant anti-ischaemic effects, whereas glibenclamide exacerbates ischaemic contracture and limits postischaemic functional recovery. The aim of the study was to investigate the ability of these compounds to influence ischaemic injury when used either alone or in combination with rapid arrest induced by a high K+ cardioplegic solution.
METHODS: Contractile function of isolated Langendorff perfused rat hearts was assessed using an intraventricular balloon. Hearts were subjected to normothermic global ischaemia (20 min) or cardioplegic arrest (35 min) with and without glibenclamide or lemakalim. Lemakalim (10 mumol.litre-1) or glibenclamide (10 mumol.litre-1) was given, in the presence or absence of cardioplegia, for 2 min immediately prior to the onset of ischaemia. The rate of ischaemia induced contractile failure, the severity of ischaemic contracture, and the degree of postischaemic functional recovery were all measured.
RESULTS: In the absence of cardioplegia, the time to contractile arrest in control hearts was 133 (SEM 4) s. This was increased by glibenclamide, to 145(6) s, and decreased by lemakalim, to 112(6) s. The time to onset of ischaemic contracture [8(1) min] was accelerated by glibenclamide [4(1) min] and delayed by lemakalim [14(1) min]. Lemakalim significantly improved the recovery of left ventricular developed pressure from 49(7)% in control hearts to 65(3)%, and left ventricular end diastolic pressure from 41(3) to 21(4) mm Hg. Hearts pretreated with glibenclamide showed similar recoveries to control hearts. During reperfusion, lemakalim exerted a transient vasodilator effect whereas glibenclamide caused a transient vasoconstriction. When either glibenclamide or lemakalim was added to a high K+ cardioplegic solution and hearts rendered ischaemic for 35 min, the ability of both compounds to influence ischaemic contracture and postischaemic functional recovery was lost. In additional studies the effect of lemakalim on the relative times to ischaemia induced mechanical failure and electrical arrest was assessed. In control hearts the time to contractile failure was 128(5) s and the time to electrical arrest was 241(30) s, while in the lemakalim treated hearts the values were 103(2) s and 509(161) s, respectively. In the lemakalim group all the hearts showed sustained ventricular arrhythmias; in the control group there were no arrhythmias.
CONCLUSIONS: Lemakalim can exert a significant anti-ischaemic effect when given alone. This effect is lost when it is used in combination with high K+ cardioplegia. The anti-ischaemic properties of lemakalim may thus be limited to its ability to accelerate contractile arrest.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291083     DOI: 10.1093/cvr/26.11.1063

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  13 in total

1.  Resting membrane potential regulates Na(+)-Ca2+ exchange-mediated Ca2+ overload during hypoxia-reoxygenation in rat ventricular myocytes.

Authors:  István Baczkó; Wayne R Giles; Peter E Light
Journal:  J Physiol       Date:  2003-06-13       Impact factor: 5.182

Review 2.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  Diazoxide Cardioprotection Is Independent of Adenosine Triphosphate-Sensitive Potassium Channel Kir6.1 Subunit in Response to Stress.

Authors:  Matthew C Henn; M Burhan Janjua; Haixia Zhang; Evelyn M Kanter; Carol M Makepeace; Richard B Schuessler; Colin G Nichols; Jennifer S Lawton
Journal:  J Am Coll Surg       Date:  2015-02-21       Impact factor: 6.113

4.  An open sarcolemmal adenosine triphosphate-sensitive potassium channel is necessary for detrimental myocyte swelling secondary to stress.

Authors:  Angela D Sellitto; Ashraf S Al-Dadah; Richard B Schuessler; Colin G Nichols; Jennifer S Lawton
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

5.  Increased tolerance to stress in cardiac expressed gain-of-function of adenosine triphosphate-sensitive potassium channel subunit Kir6.1.

Authors:  Matthew C Henn; M Burhan Janjua; Haixia Zhang; Evelyn M Kanter; Carol M Makepeace; Richard B Schuessler; Colin G Nichols; Jennifer S Lawton
Journal:  J Surg Res       Date:  2016-08-12       Impact factor: 2.192

6.  Superior diastolic function with KATP channel opener diazoxide in a novel mouse Langendorff model.

Authors:  Carol M Makepeace; Alejandro Suarez-Pierre; Evelyn M Kanter; Richard B Schuessler; Colin G Nichols; Jennifer S Lawton
Journal:  J Surg Res       Date:  2018-03-22       Impact factor: 2.192

7.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

8.  Pharmacological activation of plasma-membrane KATP channels reduces reoxygenation-induced Ca(2+) overload in cardiac myocytes via modulation of the diastolic membrane potential.

Authors:  István Baczkó; Wayne R Giles; Peter E Light
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

9.  Diazoxide protects the rabbit heart following cardioplegic ischemia.

Authors:  Jun Feng; Hongling Li; Eliot R Rosenkranz
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.396

Review 10.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

Authors:  G Leibowitz; E Cerasi
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.